These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

931 related items for PubMed ID: 25684142

  • 1. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z, Wu Y, Wang W, Wu J, Tao S, Yang X, Qiao K, Zhang J, Liu J, Fu Q, Xie Y.
    Oncogene; 2015 Oct 29; 34(44):5524-35. PubMed ID: 25684142
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 3. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z, Yuan X, Qu Y, Li X, Wu G, Li C, Zu X, Yang N, Ke X, Zhou J, Xie N, Xu X, Liu S, Shen Y, Li H, Zhang W.
    Cancer Lett; 2017 Sep 10; 403():195-205. PubMed ID: 28645563
    [Abstract] [Full Text] [Related]

  • 4. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT, Chao CC.
    Oncotarget; 2015 Nov 17; 6(36):38999-9017. PubMed ID: 26517516
    [Abstract] [Full Text] [Related]

  • 5. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L, Sun J, Chen X, Liu L, Wu D.
    J Exp Clin Cancer Res; 2019 Jul 18; 38(1):316. PubMed ID: 31319849
    [Abstract] [Full Text] [Related]

  • 6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 7. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
    Lu WJ, Chua MS, Wei W, So SK.
    Oncotarget; 2015 Oct 06; 6(30):29847-59. PubMed ID: 26359353
    [Abstract] [Full Text] [Related]

  • 8. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 9. Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation.
    Jiang N, Chen WJ, Zhang JW, Xu C, Zeng XC, Zhang T, Li Y, Wang GY.
    Oncotarget; 2015 Apr 10; 6(10):7866-79. PubMed ID: 25797263
    [Abstract] [Full Text] [Related]

  • 10. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.
    Clin Cancer Res; 2012 Sep 15; 18(18):4997-5007. PubMed ID: 22811581
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.
    Cell Signal; 2014 May 15; 26(5):1030-9. PubMed ID: 24486412
    [Abstract] [Full Text] [Related]

  • 12. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 13. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
    Shen YN, He HG, Shi Y, Cao J, Yuan JY, Wang ZC, Shi CF, Zhu N, Wei YP, Liu F, Huang JL, Yang GS, Lu JH.
    Mol Carcinog; 2017 Feb 22; 56(2):751-760. PubMed ID: 27478926
    [Abstract] [Full Text] [Related]

  • 14. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling.
    Bai XL, Zhang Q, Ye LY, Liang F, Sun X, Chen Y, Hu QD, Fu QH, Su W, Chen Z, Zhuang ZP, Liang TB.
    Oncogene; 2015 Jul 30; 34(31):4089-97. PubMed ID: 25328135
    [Abstract] [Full Text] [Related]

  • 15. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
    Peng YY, He YH, Chen C, Xu T, Li L, Ni MM, Meng XM, Huang C, Li J.
    Cancer Lett; 2016 Jun 28; 376(1):10-21. PubMed ID: 26975630
    [Abstract] [Full Text] [Related]

  • 16. UNC119 promoted cell growth and migration by Wnt/β-catenin signal and TGF-β/EMT signal pathway in hepatocellular carcinoma.
    Liu ZH, Zhang YF, Xu ZD, Z H L, Y F Z, Z D X.
    J BUON; 2018 Jun 28; 23(6):1717-1724. PubMed ID: 30610799
    [Abstract] [Full Text] [Related]

  • 17. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ.
    Cancer Res; 2011 Jun 01; 71(11):4028-39. PubMed ID: 21512140
    [Abstract] [Full Text] [Related]

  • 18. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
    Zheng Y, Jiang L, Hu Y, Xiao C, Xu N, Zhou J, Zhou X.
    BMC Cancer; 2017 Feb 28; 17(1):161. PubMed ID: 28241806
    [Abstract] [Full Text] [Related]

  • 19. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK.
    Hepatology; 2015 Aug 28; 62(2):534-45. PubMed ID: 25902734
    [Abstract] [Full Text] [Related]

  • 20. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
    Jin W, Chen L, Cai X, Zhang Y, Zhang J, Ma D, Cai X, Fu T, Yu Z, Yu F, Chen G.
    Oncol Rep; 2017 Jan 28; 37(1):273-280. PubMed ID: 27878301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.